HALO · XBRL financial data

Halozyme Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HALO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	216	230*	196	231	290	298*	265	326	354	452*	377	481
Cost of goods and services sold	55	52*	28	40	49	42*	48	46	55	79*	79	79
Research and development	17	21*	19	21	18	20*	15	18	17	—	26	28
Selling, general and administrative	35	38*	35	36	41	42*	42	42	46	77*	58	57
Operating income (loss)	88	101*	96	117	163	176*	142	202	218	(93)*	185	288
Interest expense	5	5*	5	5	5	5*	5	4	4	5*	6	6
Other income (expense)	5	5*	5	5	6	7*	7	7	5	2*	1	3
Income tax expense (benefit)	20	16*	19	24	28	41*	26	40	44	41*	30	55
Net income (loss)	82	85*	77	93	137	137*	118	165	175	(142)*	150	230
Earnings per share, basic USD per share	0.62	0.66*	0.61	0.73	1.08	1.08*	0.96	1.36	1.49	(1.20)*	1.27	1.96
Earnings per share, diluted USD per share	0.61	0.65*	0.60	0.72	1.05	1.06*	0.93	1.33	1.43	(1.16)*	1.22	1.90
Weighted average shares, basic millions of shares	132	129*	127	127	127	126*	123	121	117	118*	118	117
Weighted average shares, diluted millions of shares	134	131*	129	129	130	129*	127	124	122	123*	123	121

Fiscal quarters (HALO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	274	118	165	188	154	116	176	62	420	134	310	163
Accounts receivable	214	233	185	210	273	288	304	315	344	426	458	453
Inventory	129	128	169	159	131	142	165	182	186	176	155	137
Prepaid and other current assets	49	49	46	85	44	39	45	77	95	65	71	109
Total current assets	879	746	874	988	1,127	1,085	1,262	1,123	1,329	825	1,003	933
Property and equipment, net	37	38	42	40	40	41	40	40	41	44	47	50
Right-of-use asset	37	37	36	35	35	34	33	32	31	38	35	35
Goodwill	417	417	417	417	417	417	417	417	417	580	582	582
Total assets	1,893	1,733	1,842	1,969	2,118	2,063	2,197	2,054	2,221	2,525	2,673	2,577
Accounts payable	19	12	13	15	12	10	20	19	15	21	14	24
Accrued liabilities	95	101	118	118	96	129	130	116	111	156	140	112
Current portion of long-term debt	0	0	—	—	—	0	—	—	711	0	209	209
Total current liabilities	115	112	132	133	109	139	150	134	837	177	363	344
Long-term debt	1,498	1,499	1,501	1,503	1,504	1,506	1,507	1,509	800	2,143	1,936	1,938
Total liabilities	1,643	1,649	1,664	1,680	1,665	1,700	1,714	1,721	1,717	2,477	2,453	2,434
Retained earnings	222	91	167	261	398	360	478	361	502	55	205	151
Total stockholders' equity	249	84	178	289	453	364	482	333	504	49	220	144
Total liabilities and equity	1,893	1,733	1,842	1,969	2,118	2,063	2,197	2,054	2,221	2,525	2,673	2,577
Common shares outstanding (cover page) millions of shares	132	127	127	127	127	123	123	117	118	118	119	113

Fiscal quarters (HALO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	82	85*	77	93	137	137*	118	165	175	(142)*	150	230
Stock-based compensation	9*	10*	10	9*	13*	11*	11	12*	12*	17*	17	18*
Depreciation and amortization	3	3*	2	3	3	3*	3	3	3	3*	4	5
Net cash from operating activities	132*	102*	129	56*	115*	178*	154	100*	179*	219*	180	241*
Purchases of property and equipment	3*	3*	4	3*	2*	3*	1	2*	3*	1*	4	4*
Net cash from investing activities	(83)*	(8)*	(83)	(42)*	(167)*	29*	(90)	85*	202*	(742)*	(3)	(63)*
Share repurchases	0*	252*	0	0*	0*	250*	—	—	39*	0*	—	—
Net cash from financing activities	4*	(250)*	(0)	9*	19*	(246)*	(3)	(299)*	(22)*	240*	(2)	(326)*
Net change in cash	53*	(156)*	46	23*	(34)*	(38)*	60	(114)*	358*	(283)*	176	(148)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	66	71	(9.2)*	68.9M	36.2 quarters	Q2 FY26 10-QJun 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.